← Leaderboards
Elissa Kramer
New York University School Of Medicine
$21,006
Attributed
$21,006
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$21,006 · 1
By mechanism
M01$21,006 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Franco M Muggia$5,360,861
- Jay Cooper$168,048
- Vivian S Lee$14,934,720
- Roman Perez-Soler$12,753,063
Others in their field
Top investigators on “Antitumor Antibody”
- Carlos L Arteaga · Vanderbilt University$15,203,138
- Paul M Sondel · University Of Wisconsin Madison$13,731,361
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$13,559,983
- Thomas S. Kupper · Dana-Farber Cancer Institute$11,993,358
- T.-C. Wu · Howard University$9,126,571
- John H Sampson · Duke University$8,973,197
Research focus
Antitumor AntibodyBreast NeoplasmsClinical ResearchClinical Trial Phase ICombination Cancer TherapyHuman SubjectHuman Therapy EvaluationImmunoconjugatesMetastasisMonoclonal AntibodyNeoplasm /Cancer ChemotherapyNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Radionuclide TherapyNeoplasm /Cancer Relapse /RecurrenceRadionuclidesTopotecanYttrium
Grant awards (4)
MONOCLONAL ANTIBODY-BASED STRATEGIES FOR TREATMENT OF BREAST CANCER$0
M01 · FY2002 · RR
MONOCLONAL ANTIBODY-BASED STRATEGIES FOR TREATMENT OF BREAST CANCER$0
M01 · FY2001 · RR
MONOCLONAL ANTIBODY-BASED STRATEGIES FOR TREATMENT OF BREAST CANCER$21,006
M01 · FY2000 · RR
MONOCLONAL ANTIBODY-BASED STRATEGIES FOR TREATMENT OF BREAST CANCER$0
M01 · FY2000 · RR